Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

证券代码：603102 证券简称：百合股份 公告编号：2025-020 威海百合生物技术股份有限公司 董事减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 上述减持主体无一致行动人 1 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相 应顺延。 (一)相关股东是否有其他安排 □是 √否 重要内容提示： 董事持股的基本情况 截至本公告披露之日，董事王文通先生持有公司股份 1,697,518 股，占公司 总股本的 2.65%，上述股份全部来源于公司首次公开发行股票前已持有的股份。 减持计划的主要内容 王文通计划通过集中竞价方式减持公司股份不超过 424,000 股，不超过公司 总股本的 0.6625%，本减持计划在本公告披露之日起十五个交易日后的三个月内 进行（窗口期不减持）。若在减持计划实施期间公司发生送股、资本公积金转增 股本等股份变动事项，王文通可以根据公司股本变动情况对减持计划进行相应调 整。 | 股东名称 | 王文通 | | | --- | --- ...

百合股份（603102）公告，董事王文通计划通过集中竞价方式减持公司股份不超过42.4万股，不超过公 司总股本的0.6625%。 ...

Core Viewpoint - The current Chinese nutrition and health food market is undergoing significant transformation, with new consumption trends creating opportunities for growth, particularly for leading B-end enterprises [1] New Channels - Four core growth directions identified: interest e-commerce and grass-planting communities, online cross-border sales, private domain e-commerce, and new retail offline. a) Douyin-driven interest e-commerce and Xiaohongshu-based grass-planting communities are thriving, with Douyin's health product sales expected to grow by 52.5% year-on-year in 2024; b) Online cross-border health products are experiencing explosive growth, with Douyin's global purchase GMV projected to increase by 204% year-on-year in 2024; c) Private domain e-commerce is characterized by high average order value and strong repurchase rates, expected to develop rapidly; d) Offline new retail supermarkets are in the process of expanding, with significant growth anticipated in health product sales [2] New Trends - The diversification of efficacy and the emergence of snack-like dosage forms are raising demands on supply-side R&D capabilities. The "self-care economy" is flourishing, leading consumers to have more specific and personalized efficacy expectations; emerging dosage forms like gummies and beverages offer palatability and convenience, fostering daily consumption habits [3] All-Age Groups - The consumer base for health products is becoming increasingly age-diverse. Young consumers are emerging as a new force in health product consumption due to the popularization of health and wellness concepts and work-related stress. Initially dominated by the "her economy," focusing on oral beauty, weight management, and women's health, the market is now seeing active participation from the "his economy," with manufacturers focusing on liver protection and fatigue resistance [4] Advantages of Leading B-End Enterprises - As new consumer brands in the nutrition and health food industry rise, C-end sales are expected to grow at a mid-to-high single-digit CAGR. The market for dietary supplements in China is projected to reach 232.34 billion yuan in 2024, with a year-on-year growth of 3.7%. Despite a slowdown due to a high base in 2023 and significant declines in pharmacy channels, the long-term growth trend remains intact. The per capita consumption of nutrition and health products in China is significantly lower than in mature markets like the US, Japan, and Australia, indicating potential for growth. The "Healthy China" strategy, stable economic development, and the expansion of the consumer base across all age groups are expected to drive continued growth in the C-end market. Enterprises with stronger R&D capabilities and scale advantages are likely to capture higher market shares, with the B-end market further concentrating towards leading players [5]

A股食品股多数高开，劲仔食品开涨超5%，百合股份开涨超3%，盐津铺子、麦趣尔等跟涨。 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-019 威海百合生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●威海百合生物技术股份有限公司（以下简称"公司"）股票于 2025 年 累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交 易异常波动情况。 ●经公司自查并向控股股东、实际控制人书面发函查证，截至本公告披 露日，确认不存在应披露而未披露的重大事项或重要信息。 一、股票交易异常波动的具体情况 公司股票于 2025 年 5 月 15 日、5 月 16 日、5 月 19 日连续三个交易日 内日收盘价格涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》 的有关规定，属于股票交易异常波动情况。 二、公司关注并核实的相关情况 （一）生产经营情况。 经公司自查，公司目前生产经营活动一切正常。市场环境、行业政策没 有发生重大调整，生产成本和销售等情况没有出现大幅波动，内部生产经营 秩序正常。 （二）重大事项情况。 经公司自查，并向 ...

威海百合生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●威海百合生物技术股份有限公司（以下简称"公司"）股票于 2025 年 5 月 15 日、5 月 16 日、5 月 19 日连续三个交易日内日收盘价格涨幅偏离值 累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交 易异常波动情况。 ●经公司自查并向控股股东、实际控制人书面发函查证，截至本公告披 露日，确认不存在应披露而未披露的重大事项或重要信息。 一、股票交易异常波动的具体情况 证券代码：603102 证券简称：百合股份 公告编号：2025-019 （四）其他股价敏感信息。 经公司核实，公司未发现其他可能对公司股价产生较大影响的重大事 件，公司董事、监事、高级管理人员、控股股东及实际控制人及其一致行动 人在公司本次股票异常波动期间不存在买卖公司股票的情况。 三、相关风险提示 公司股票于 2025 年 5 月 15 日、5 月 16 日、5 月 19 日连续三个交易日 内日收盘价格涨幅偏离值累计 ...

本人已于 2025年5月19日收到贵公司发来的《威海百合生物技 术股份有限公司股票交易异常波动的问询函》,经本人认真自查,现 回复如下: 本人为威海百合生物技术股份有限公司 (以下简称"上市公司") 的控股股东和实际控制人,截止目前不存在影响上市公司股票交易异 常波动的重大事项,不存在其他应披露而未披露的重大信息,包括但 关于威海百合生物技术股份有限公司 股票交易异常波动问询函的回函 威海百合生物技术股份有限公司: 项、业务重组、股份回购、股权激励、破产重整、重大业务合作、引 进战略投资者等重大事项。 本人在公司本次股票异常波动期间,不存在买卖公司股票的行为。 特此回函! 控股股东、实际控制人： 云| 系イ 大 2025 年 5 月'19 日 - and allery of the 不限于筹划涉及上市公司的重大资产重组、股份发行、重大交易类事 ...

百合股份（603102）发布异动公告，经公司自查并向控股股东、实际控制人书面发函查证，确认不存在 应披露而未披露的重大事项或重要信息。公司目前生产经营活动一切正常。市场环境、行业政策没有发 生重大调整，生产成本和销售等情况没有出现大幅波动，内部生产经营秩序正常。公司基本面未发生重 大变化。 ...

作者 | 守望者 来源 | 守望核心 导语： 拆解宠物板块持续新高背后的三大预期与核心标的逻辑。 宠物板块持续新高的背后市场在交易什么预期，借助公开资料，理一下宠物板块的β及选股思路， 以及个股的核心看点 。 一、大背景 宠物经济蓬勃发展的内核是宠物的 "人格化、家人化" ， 年轻一代将宠物视为"家人"的情感价值重 构。 1、宠物经济正是基于这一情感纽带蓬勃发展，从提供高品质的宠物食品、个性化的宠物用品，满 足宠物的物质需求； 2、到宠物医疗、保险，为宠物的健康保驾护航； 3、再到宠物美容、摄影、社交活动等，满足主人与宠物之间情感互动的精神需求。 每一个细分领域，让宠物真正融入家庭生活，也让宠物经济的内涵和外延得以不断拓展和深化 。 二、宠物是一个大赛道 1、横向对比化妆品、白酒、食品等来看， 宠物赛道是消费里面少有量价齐升的板块 ，并且随着单 身经济及消费方式的转变， 从实物消费到情绪消费的转变 ，相信大家多少在家里面都多少有一些 宠物（常见的是猫、狗，稀罕的是鸟、仓鼠、乌龟、蛇等），宠物恰逢其时，目前A股从宠物食品 到医疗已经形成一个完整的贝塔。 C、主业稳健，每年贡献净利润大几千万，收购的淘通科技可以贡 ...